Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | STAT1 | P42224 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399339 | 0.84 | KDM4E (0.72) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL18885210 | 0.82 | MAPT (0.71) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL706743 | 0.82 | POLB (0.70) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL20339738 | 0.80 | KDM4E (0.67) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL21143527 | 0.79 | MAPT (0.68) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL20621396 | 0.79 | MAPT (0.81) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL18920608 | 0.79 | ALDH1A1 (0.83) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL18920553 | 0.79 | KDM4E (0.65) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL12417204 | 0.79 | MAPT (0.66) | MAPTNPC1RAB9AKDM4EHSP90AA1 | |
| SCHEMBL31358657 | 0.79 | MAPT (0.65) | MAPTNPC1RAB9AKDM4EHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574070-B | Synthesis method of substituted urea compound | 西华大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-112574070-A | Synthesis method of substituted urea compound | 西华大学 | 2021-03-30 | — | — | CN | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | GB006 INC (US) | 2020-04-23 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2917203-B1 | METHOD FOR IDENTIFYING MYC INHIBITORS | DANA FARBER CANCER INST INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| CN-103509009-A | 2-substituted-5-phenyl furan compound, and preparation method, pharmaceutical composition and application thereof | SHANGHAI INST MATERIA MEDICA | 2014-01-15 | — | — | CN | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| EP-2054383-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | MAPT 1920/4885NPC1 3467/4885RAB9A 1186/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | MAPT 1886/4885NPC1 4542/4885RAB9A 4092/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | MAPT 2072/4885NPC1 2933/4885RAB9A 3936/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | MAPT 4443/4885NPC1 2689/4885RAB9A 3965/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | MAPT 4052/4885NPC1 1376/4885RAB9A 4156/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | MAPT 4443/4885NPC1 2689/4885RAB9A 3965/4885 |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | MCL1, ABL1, FLT3 | MAPT 4443/4885NPC1 2689/4885RAB9A 3965/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | MAPT 2881/4885NPC1 3112/4885RAB9A 2340/4885 |
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | ITGA1, ITGA4, ITGA2 | MAPT 4821/4885NPC1 2602/4885RAB9A 510/4885 |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | BRD3, BRD2, BRD4 | MAPT 2993/4885NPC1 1443/4885RAB9A 2520/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | MAPT 2072/4885NPC1 2933/4885RAB9A 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.